Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Medroxyprogesterone depot - Pfizer

Next Previous
Drug Profile

Medroxyprogesterone depot - Pfizer

Alternative Names: depo medroxyprogesterone acetate; Depo subQ in Uniject; Depo-subQ provera 104; DMPA -Pfizer; DMPA-SC; Medroxiprogesterone acetate; Sayana; Sayana Press; Sayana press

Latest Information Update: 04 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antineoplastics; Hormonal replacements; Progesterone congeners; Progestogen-only oral contraceptives
  • Mechanism of Action Interleukin 6 receptor antagonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain; Pregnancy
  • Registered Endometriosis

Most Recent Events

  • 16 Sep 2021 Pfizer initiated enrolment in a phase I trial for Pregnancy (Prevention) in Belgium (SC) (EudraCT2021-001035-54) (NCT04893798)
  • 24 May 2021 Pfizer plans a phase I trial in Healthy volunteers (SC), In July 2021 (NCT04893798)
  • 17 Jan 2018 No development reported - Preregistration for Pregnancy (Prevention) in Pakistan (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top